Tokyo, May 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061708) titled 'Pilot study investigating the effects of forefoot design of ankle-foot ortho... Read More
Tokyo, May 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061705) titled 'Study to investigate the effects of incretin drugs on depression, quality of... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evalu... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending D... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combine... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... Read More
Singapore, May 27 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More